Tag: Squibbs
Bristol Myers Squibb’s targeted AML drug Idhifa fails to extend patients’...
Back in 2017, the FDA cleared Celgene's acute myeloid leukemia therapy Idhifa based on complete remission data. But fast forward to today, and the drug has...
Bristol Myers Squibb’s Zeposia angles for lucrative ulcerative colitis nod with...
Bristol Myers Squibb notched a big win with its recent approval of multiple sclerosis drug Zeposia, a Celgene pipeline pickup with blockbuster aspirations. Not content to ride its...
Bristol Myers Squibb’s Zeposia launches into crowded MS market
When Bristol Myers Squibb nabbed Celgene's long-sought FDA nod for multiple sclerosis drug Zeposia, the COVID-19 pandemic was in full swing—not the ideal time...